Cite

HARVARD Citation

    Yip, L. et al. (2017). The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment. Journal of thrombosis and haemostasis. pp. 2466-2467. [Online]. 
  
Back to record